• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices.真实世界社区心血管实践中梗阻性肥厚型心肌病患者的特征。
Am J Cardiol. 2022 Jul 1;174:120-125. doi: 10.1016/j.amjcard.2022.03.023. Epub 2022 Apr 23.
2
Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy.种族与肥厚型心肌病患者疾病表现和临床结局的相关性。
JAMA Cardiol. 2020 Jan 1;5(1):83-91. doi: 10.1001/jamacardio.2019.4638.
3
Impact of type 2 diabetes mellitus on mid-term mortality for hypertrophic cardiomyopathy patients who underwent septal myectomy.2 型糖尿病对接受室间隔心肌切除术的肥厚型心肌病患者中期死亡率的影响。
Cardiovasc Diabetol. 2020 May 13;19(1):64. doi: 10.1186/s12933-020-01036-1.
4
Does ablation of atrial fibrillation at the time of septal myectomy improve survival of patients with obstructive hypertrophic cardiomyopathy?在室间隔肌切除术时进行房颤消融是否能提高梗阻性肥厚型心肌病患者的生存率?
J Thorac Cardiovasc Surg. 2021 Mar;161(3):997-1006.e3. doi: 10.1016/j.jtcvs.2020.08.066. Epub 2020 Aug 25.
5
Septal myectomy after failed alcohol ablation: Does previous percutaneous intervention compromise outcomes of myectomy?酒精消融失败后的间隔心肌切除术:既往经皮介入是否会影响心肌切除术的结果?
J Thorac Cardiovasc Surg. 2015 Jul;150(1):159-67.e1. doi: 10.1016/j.jtcvs.2015.03.044. Epub 2015 Mar 31.
6
Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy.肥厚型梗阻性心肌病患者行心肌切除术同期行房颤消融术。
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1536-1542.e2. doi: 10.1016/j.jtcvs.2017.08.063. Epub 2017 Sep 1.
7
Sex differences in clinical outcomes for obstructive hypertrophic cardiomyopathy in the USA: a retrospective observational study of administrative claims data.美国梗阻性肥厚型心肌病临床结局的性别差异:基于行政索赔数据的回顾性观察研究。
BMJ Open. 2022 Mar 9;12(3):e058151. doi: 10.1136/bmjopen-2021-058151.
8
Hypertrophic obstructive cardiomyopathy.肥厚型梗阻性心肌病。
Lancet. 2017 Mar 25;389(10075):1253-1267. doi: 10.1016/S0140-6736(16)31321-6. Epub 2016 Nov 30.
9
Ambulatory monitoring of aborted sudden cardiac death related to hypertrophic cardiomyopathy.肥厚型心肌病相关心脏性猝死未遂的动态监测
Nat Clin Pract Cardiovasc Med. 2005 Dec;2(12):659-62; quiz following 662. doi: 10.1038/ncpcardio0381.
10
Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.肥厚型梗阻性心肌病行间隔减容治疗后降低心源性猝死风险的研究进展
Heart Fail Rev. 2019 May;24(3):359-366. doi: 10.1007/s10741-018-09767-w.

引用本文的文献

1
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten.肝损伤或肾损伤对阿菲卡明药代动力学的影响。
Clin Pharmacokinet. 2025 Mar;64(3):397-406. doi: 10.1007/s40262-025-01481-9. Epub 2025 Feb 5.
2
Impact of Genetic Testing on the Diagnosis, Management, and Prognosis of Hypertrophic Cardiomyopathy: A Systematic Review.基因检测对肥厚型心肌病诊断、管理及预后的影响:一项系统评价
Cureus. 2024 Oct 7;16(10):e70993. doi: 10.7759/cureus.70993. eCollection 2024 Oct.
3
Differences in Healthcare Resource Use and Cost by Pharmacotherapy Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Real-World Analysis of Claims Data.
有症状的梗阻性肥厚型心肌病患者药物治疗的医疗资源使用和成本差异:索赔数据的真实世界分析
Am J Cardiovasc Drugs. 2024 Nov;24(6):801-811. doi: 10.1007/s40256-024-00674-0. Epub 2024 Aug 22.
4
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration.肥厚型心肌病患者中马卡坦的药代动力学特征,以指导剂量调整。
CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1462-1475. doi: 10.1002/psp4.13197. Epub 2024 Aug 13.
5
Clinical Characteristics and Healthcare Resource Utilization among Patients with Obstructive Hypertrophic Cardiomyopathy Treated in a Range of Settings in the United States.美国不同医疗机构中接受治疗的梗阻性肥厚型心肌病患者的临床特征及医疗资源利用情况
J Clin Med. 2022 Jul 4;11(13):3898. doi: 10.3390/jcm11133898.

真实世界社区心血管实践中梗阻性肥厚型心肌病患者的特征。

Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices.

机构信息

Cytokinetics, Incorporated, Health Economics and Outcomes Research, South San Francisco, California.

Cytokinetics, Incorporated, Health Economics and Outcomes Research, South San Francisco, California.

出版信息

Am J Cardiol. 2022 Jul 1;174:120-125. doi: 10.1016/j.amjcard.2022.03.023. Epub 2022 Apr 23.

DOI:10.1016/j.amjcard.2022.03.023
PMID:35473784
Abstract

The clinical profile of patients with obstructive hypertrophic cardiomyopathy (oHC) is not well characterized, with little evidence outside selected referral populations. Using longitudinal medical claims data from a United States nationwide database, we retrospectively identified adults who were newly diagnosed with oHC. Clinical characteristics were compared from 1 year before diagnosis and at the 2-year follow-up. Patients (N = 1,841) with oHC (age 63 ± 15 years; 52% were male) with geographic representation across the United States were identified. Most patients received care within community-based cardiovascular practices and 7% at referral hypertrophic cardiomyopathy (HC) centers. Baseline diagnostic procedures included electrocardiogram (66%), echocardiogram (51%), magnetic resonance imaging (4%), and HC genetic testing (0.7%). Baseline co-morbidities were hypertension (59%), coronary artery disease (30%), diabetes (19%), and atrial fibrillation (19%). For all HC-related medications, use significantly increased after diagnosis. During follow-up, 144 patients (8%) received an implantable cardioverter-defibrillator for sudden death prevention, 99 underwent septal myectomy (5%), and 24 underwent alcohol septal ablation (1%). By the 1-year follow-up, 2% of patients had sudden cardiac arrest and 26% had atrial fibrillation, and heart failure increased from 16% to 27%. In conclusion, in a community-based population of patients with oHC, patients' age at diagnosis of oHC was older than reported for referral populations and patients had a significant co-morbidity burden. Cardiovascular medication use was appropriate, but the rate of guideline-supported surgical procedures was low.

摘要

患有梗阻性肥厚型心肌病 (oHC) 的患者的临床特征尚未得到很好的描述,除了在选定的转诊人群之外,几乎没有其他证据。我们使用来自美国全国性数据库的纵向医疗索赔数据,回顾性地确定了新诊断为 oHC 的成年人。比较了从诊断前 1 年和 2 年随访时的临床特征。在美国各地具有地理代表性的患者 (N=1841) 患有 oHC(年龄 63 ± 15 岁;52%为男性)。大多数患者在社区为基础的心血管实践中接受治疗,7%在转诊肥厚型心肌病 (HC) 中心接受治疗。基线诊断程序包括心电图 (66%)、超声心动图 (51%)、磁共振成像 (4%) 和 HC 基因检测 (0.7%)。基线合并症包括高血压 (59%)、冠状动脉疾病 (30%)、糖尿病 (19%)和心房颤动 (19%)。所有与 HC 相关的药物在诊断后均显著增加。在随访期间,144 名患者 (8%)因预防猝死而植入了植入式心脏复律除颤器,99 名接受了室间隔心肌切除术 (5%),24 名接受了酒精室间隔消融术 (1%)。到 1 年随访时,有 2%的患者发生了心搏骤停,26%的患者发生了心房颤动,心力衰竭从 16%增加到 27%。总之,在社区为基础的 oHC 患者人群中,患者 oHC 的诊断年龄大于转诊人群报告的年龄,且患者合并症负担较重。心血管药物的使用是恰当的,但指南支持的手术治疗率较低。